Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1101 to 1150 of 4090 results for patient

  1. Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services (CG136)

    This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.

  2. Implanting a baroreceptor stimulation device for resistant hypertension (HTG387)

    Evidence-based recommendations on implanting a baroreceptor stimulation device for resistant hypertension. This involves using electrical impulses from the device that stimulate baroreceptors to help the body lower blood pressure.

  3. Laparoscopic cystectomy (HTG181)

    Evidence-based recommendations on laparoscopic cystectomy. This involves removing the bladder using small cuts in the abdomen (keyhole surgery).

  4. Sacral nerve stimulation for faecal incontinence (HTG61)

    Evidence-based recommendations on sacral nerve stimulation for faecal incontinence. This involves using electrodes inserted under the skin to produce pulses of electricity thought to affect the nerves controlling the lower part of the bowel and the anal sphincter.

  5. Magnetic resonance therapy for knee osteoarthritis (HTG588)

    Evidence-based recommendations on magnetic resonance therapy for knee osteoarthritis in adults. This involves placing a magnetic resonance device over the knee to stimulate cartilage to heal and relieve the symptoms of osteoarthritis.

  6. Laparoscopic augmentation cystoplasty (including clam cystoplasty) (HTG207)

    Evidence-based recommendations on Laparoscopic augmentation cystoplasty (including clam cystoplasty). This involves sewing or stapling a tissue graft from a section of the small intestine (ileum), colon or other substitutes to the urinary bladder.

  7. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  8. Balloon cryoablation for squamous dysplasia of the oesophagus (HTG560)

    Evidence-based recommendations on balloon cryoablation for squamous dysplasia of the oesophagus. This involves using a balloon filled with cold gas to destroy abnormal cells.

  9. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

  10. Endoscopic dacryocystorhinostomy (HTG68)

    Evidence-based recommendations on endoscopic dacryocystorhinostomy for treating lacrimal sac or nasolacrimal duct obstruction. This involves making a connection that bypasses the blocked area so that the tears can drain straight into the nose.

  11. Digitally enabled therapies for adults with depression: early value assessment (HTG675)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression.

  12. Minimally invasive total hip replacement (HTG236)

    Evidence-based recommendations on minimally invasive total hip replacement. This involves replacing the damaged hip joint (the top part of the upper leg bone and the socket in the hip bone that it fits into) with an artificial one.

  13. Gastroelectrical stimulation for gastroparesis (HTG341)

    Evidence-based recommendations on gastroelectrical stimulation for gastroparesis. This involves using a stimulating device to send electrical impulses to the stomach muscles to help them work normally.

  14. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  15. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

  16. Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (HTG489)

    Evidence-based recommendations on selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma in adults. This involves injecting tiny radioactive ‘beads’ into blood vessels that supply the liver, where they become trapped and release radiation directly into the cancer cells.

  17. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  18. Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136)

    Evidence-based recommendations on bevacizumab (Avastin [originator] and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

  19. Stereotactic radiosurgery for trigeminal neuralgia (HTG608)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focusing radiation on the trigeminal nerve to damage it, thereby relieving pain.

  20. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)

    Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.

  21. Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (HTG499)

    Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.

  22. Tinnitus: assessment and management (NG155)

    This guideline covers the assessment, investigation and management of tinnitus in primary, community and secondary care. It offers advice to healthcare professionals on supporting people presenting with tinnitus and on when to refer for specialist assessment and management.

  23. Cyanoacrylate instillation for occlusion of parotid sinuses (HTG20)

    Evidence-based recommendations on cyanoacrylate instillation for occlusion of parotid sinuses. This involves injecting a solution of lipiodiol and cyanoacrylate via the sinus into the parotid gland, sealing the sinus.

  24. Fallopian tube recanalisation by guidewire (HTG44)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this does not unblock it, using a guidewire.

  25. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date: TBC

  26. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

  27. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

  28. Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (HTG305)

    Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.

  29. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.

  30. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

    Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  31. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.

  32. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  33. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  34. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (HTG345)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  35. Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (HTG569)

    Evidence-based recommendations on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. This involves surgically removing visible cancer and bathing the abdominal cavity with heated chemotherapy fluid to reach any remaining cancer cells.

  36. Joint distraction for ankle osteoarthritis (HTG393)

    Evidence-based recommendations on joint distraction for ankle osteoarthritis in adults. This involves fixing a metal frame around the ankle and pulling the joint slightly apart using the frame to allow cartilage regrowth.

  37. Functional electrical stimulation for drop foot of central neurological origin (HTG178)

    Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.

  38. Midostaurin for untreated acute myeloid leukaemia (TA523)

    Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

  39. Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)

    Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.

  40. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)

    Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.

  41. Immunosuppressive therapy for kidney transplant in adults (TA481)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  42. Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers (HTG243)

    Evidence-based recommendations on percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. This involves passing a device through a large vessel in the groin up into the heart and closing/blocking the hole in the wall.

  43. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

  44. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  17 September 2026

  45. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]

    In development Reference number: GID-TA11742 Expected publication date:  29 July 2026

  46. Tonsillectomy using ultrasonic scalpel (HTG116)

    Evidence-based recommendations on tonsillectomy using ultrasonic scalpel. This involves using high-energy waves to cut the tonsils out and stop the bleeding at the same time.

  47. Vagus nerve stimulation for refractory epilepsy in children (HTG25)

    Evidence-based recommendations on vagus nerve stimulation for refractory epilepsy in children. This involves placing a device under the skin to send a burst of nerve messages through the nerve.

  48. Breast reconstruction using lipomodelling after breast cancer treatment (HTG280)

    Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.

  49. Transvaginal laser therapy for stress urinary incontinence (HTG581)

    Evidence-based recommendations on transvaginal laser therapy for urinary stress incontinence. This involves using a laser in the vagina to strengthen the vaginal walls, to help support the bladder and reduce symptoms of urinary stress incontinence.

  50. Danis stent for acute oesophageal variceal bleeding (HTG574)

    Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.